



**Biocon Limited**

20th KM Hosur Road

Electronics City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

Date of submission: December 17, 2018

To The Secretary BSE Limited Department of Corporate Services PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, BandraKurla Complex Mumbai – 400 050 Scrip Code- BIOCON
--	--

Dear Sir/Madam,

**Sub: Biocon's APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations**

**Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

*"This is to inform you that the U.S. FDA conducted a GMP inspection of our APIs manufacturing facility at Telangana from Dec 12- Dec 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects our strong commitment to quality and cGMP compliance." - Company Spokesperson*

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,  
Yours faithfully  
For Biocon Limited

Satish Kumar S S  
Company Secretary and Compliance Officer